Amgen Inc Stock Price, News & Analysis

Amgen (NASDAQ:AMGN) announced FDA approval of UPLIZNA (inebilizumab-cdon) on December 11, 2025 for treatment of adults with generalized myasthenia gravis (gMG) who are anti-AChR and anti-MuSK antibody positive.

Approval is supported by the Phase 3 MINT trial showing durable symptom control (MG-ADL difference at Week 26: -4.2 vs -2.2, 1.9-point treatment effect; AChR+ exploratory Week 52 difference: 2.8 points). UPLIZNA is the first CD19-targeted B cell therapy approved for these gMG subtypes, dosed twice yearly after two loading doses. Most common adverse reactions were headache and infusion-related reactions. UPLIZNA is Amgen's third indication after June 2020 and April 2025 approvals.

Amgen (NASDAQ:AMGN) announced a $2.52 per share dividend for Q1 2026. The Board declared the dividend on Dec 9, 2025, with a record date of February 13, 2026 and a payment date of March 6, 2026.

This dividend applies to all stockholders of record as of the close of business on the record date.

Amgen (NASDAQ:AMGN) will present at Citi's 2025 Global Healthcare Conference on December 3, 2025 at 1:45 p.m. ET.

Presenters are Peter Griffith, executive vice president and chief financial officer, and Jay Bradner, executive vice president of Research and Development. The presentation will be webcast live and available to media, investors and the public on Amgen's investor website, with the webcast archived for replay for at least 90 days.

Amgen (NASDAQ:AMGN) will present at the 8th annual Evercore ISI HealthCONx Conference on December 3, 2025 at 10:00 a.m. ET. Presenters are Peter Griffith, executive vice president and chief financial officer, and Jay Bradner, executive vice president of Research and Development.

The presentation will be webcast live and available to the media, investors and the public via Amgen's investor website. Webcast details and links appear on Amgen's Investor Relations Events Calendar, and the archived replay will be available for at least 90 days after the event.

Amgen (NASDAQ: AMGN) announced that the FDA granted full approval to IMDELLTRA (tarlatamab-dlle) on Nov 19, 2025 for adult patients with extensive stage small cell lung cancer (ES-SCLC) with progression after platinum-based chemotherapy. The decision converts prior accelerated approval based on the global Phase 3 DeLLphi-304 trial, which showed a 40% reduction in risk of death versus standard chemotherapy (median overall survival 13.6 vs. 8.3 months; HR 0.60; P < 0.001).

The NCCN Guidelines were updated to list tarlatamab as the only Category 1 preferred option in this setting. Safety in DeLLphi-304 was consistent with known profile: fewer Grade ≥3 adverse events versus chemotherapy (54% vs. 80%); common IMDELLTRA toxicities included neutropenia (4%), lymphopenia (4%), and primarily low-grade cytokine release syndrome.

Amgen (NASDAQ:AMGN) reported Phase 3 VESALIUS-CV results showing Repatha (evolocumab) reduced first major adverse cardiovascular events by 25% (3‑P MACE) in >12,000 high‑risk adults without prior heart attack or stroke when added to LDL‑lowering therapy.

The trial also showed a 36% reduction in heart attack, a 19% reduction in 4‑P MACE, and median achieved LDL‑C of 45 mg/dL versus 109 mg/dL for placebo. No new safety signals were identified. Results presented at AHA 2025 and published in NEJM.

Amgen (NASDAQ:AMGN) reported Q3 2025 revenues of $9.6 billion, up 12% year-over-year, with product sales also up 12% driven by 14% volume growth and a 4% decline in net selling price. GAAP EPS rose 14% to $5.93; non-GAAP EPS was $5.64. GAAP operating margin improved to 27.6% while non-GAAP margin fell to 47.1%. The company generated $4.2 billion free cash flow in Q3 and retired $1.6 billion of debt in the quarter ($6.0 billion YTD). Management reiterated full-year 2025 guidance: revenues $35.8B–$36.6B, GAAP EPS $13.76–$14.60, non-GAAP EPS $20.60–$21.40.

Amgen (NASDAQ:AMGN) announced its 2025 fourth-quarter dividend: a cash dividend of $2.38 per share. The Board declared the dividend on Oct 31, 2025, with payment on December 12, 2025 to shareholders of record as of the close of business on November 21, 2025.

Amgen (NASDAQ:AMGN) will present late-breaking results from the Phase 3 VESALIUS-CV trial of Repatha (evolocumab) at the American Heart Association Scientific Sessions on November 8, 2025 at 9:10 a.m. CST. The trial met its dual primary endpoints, showing Repatha significantly reduced major adverse cardiovascular events (MACE) in high-risk patients without prior heart attack or stroke, making it the first PCSK9 inhibitor to show this benefit in that population.

Amgen will also present large real-world studies: VESALIUS-REAL (observational, >1.1 million patients across 11 countries) on lipid management and MACE incidence, and REPATHA-CE, the largest real-world study of Repatha showing a reported four-year risk reduction versus untreated patients. Multiple additional abstracts and session times span November 8–10, 2025.